TABLE 1.
Comparison of the prevalence of overweight and obesity in children with ASD treated with risperidone and the general pediatric population using IOTF criteria (n = 134).
| Overweight | Obesity | |||||||
|---|---|---|---|---|---|---|---|---|
| Healthy children (n = 855 from 9,287) (Jitnarin et al., 2011) | Children with ASD (n = 29 from 134) | Odds ratio (95%confidence intervals) | p-value | Healthy children (n = 604 from 9,287) (Jitnarin et al., 2011) | Children with ASD (n = 29 from 134) | Odds ratio (95%confidence intervals) | p-value | |
| Total | 855 (9.20%) | 29 (21.60%) | 2.85 (1.24–6.56) | 0.01* | 604 (6.50%) | 29 (21.60%) | 3.79 (1.53–9.33) | 0.002* |
| Age group | ||||||||
| 3–5 years | 242 (2.60%) | 0 (0.00%) | 0.32 (0.03–3.16) | 0.37 a | 269 (2.90%) | 0 (0.00%) | 0.32 (0.03–3.16) | 0.3a |
| 6–11 years | 390 (4.20%) | 15 (11.20%) | 2.97 (0.91–9.66) | 0.06 | 251 (2.70%) | 20 (14.90%) | 5.70 (1.59–20.38) | 0.01* |
| 12–18 years | 223 (2.40%) | 14 (10.40%) | 5.44 (1.16–25.52) | 0.02* | 84 (0.90%) | 9 (6.70%) | 7.45 (0.90–61.73) | 0.03* |
Data analyzed with the chi-square test.
a
Data analyzed with Fisher’s exact test.
*
Statistical significance of p-value < 0.05.